Biomerica, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biomerica, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $47 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $46 tied up three years earlier. More money tied up than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-82.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 79% of Healthcare companies in United States.
Cash Locked Ratio
$47For every $100 of sales, $47 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $46 tied up three years earlier.
More money tied up than 91% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 17%
Sales fell 17% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-17% / -53%In 3 years sales changed by -17% while total assets changed by -53%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-6.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 56% of Healthcare companies in United States.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 81% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 79% of Healthcare companies in United States.
Tangible Net Worth Ratio
92%Of every $100 of net worth, $92 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 75% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Biomerica, Inc. made a loss over the last year. Biomerica, Inc. owes $0.61 for every $1 it owns. Biomerica, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results May 2026.
P/E ratio
LossBiomerica, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.94The share price is 2.94 times Biomerica, Inc.'s book value per share, higher than 54% of Healthcare companies in United States.
Market cap
$8 MThe total market value of all of Biomerica, Inc.'s shares at today's price (share price × number of shares), smaller than 90% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$3 MWhat Biomerica, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 May 2026).
Book value per share
$0.57Net worth divided by the number of shares. The share price of $1.68 is 2.9 times this, which is the P/B above.
Return on equity (ROE)
-113.8%Biomerica, Inc. lost 113.8% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
Owes vs Owns
0.61×Biomerica, Inc. owes $0.61 for every $1 it owns (moderate), higher than 66% of Healthcare companies in United States.
Dividend yield
NoneBiomerica, Inc. does not currently pay a dividend.
Revenue growth
-16%Revenue fell 16% in the year to May 2026, and shrank 6% a year on average over 3 years.
Profit growth
LossBiomerica, Inc. made a loss in each of the last two years.
Profit margin
-84.8%Biomerica, Inc. lost $85 for every $100 of revenue.
Cash vs debt
Net debtBiomerica, Inc. had $1 M more debt than cash (net debt) at May 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biomerica, Inc.: $8 M ÷ $3 M (31 May 2026) = 2.9.
What is Biomerica, Inc.'s return on equity?
Biomerica, Inc. lost 113.8% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
How much does Biomerica, Inc. owe compared with what it owns?
Biomerica, Inc. owes $0.61 for every $1 it owns (moderate), higher than 66% of Healthcare companies in United States.
Does Biomerica, Inc. pay a dividend?
No. Biomerica, Inc. does not currently pay a dividend.
Is Biomerica, Inc.'s revenue growing?
Revenue fell 16% in the year to May 2026, and shrank 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.